Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study

被引:25
|
作者
Rhee, Harin [1 ,2 ]
Berenger, Brendan [1 ]
Mehta, Ravindra L. [1 ]
Macedo, Etienne [1 ]
机构
[1] Univ Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
[2] Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan, South Korea
基金
美国国家卫生研究院;
关键词
CONTINUOUS RENAL REPLACEMENT; SYSTEMIC HEPARIN ANTICOAGULATION; CRITICALLY-ILL PATIENTS; CARE;
D O I
10.1053/j.ajkd.2021.01.017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Regional citrate anticoagulation (RCA) is the preferred anticoagulation method for continuous kidney replacement therapy (CKRT) recommended by KDIGO. Limited availability of calcium-free solutions often imposes challenges to the implementation of RCA for CKRT (RCA-CKRT). The principal purpose of this study was to characterize the outcomes of RCA-CKRT using calcium-containing solutions. Study Design: Retrospective cohort study. Setting & Participants: We evaluated the safety and efficacy of RCA-CKRT with calcium-containing dialysate and replacement fluid used for 128 patients. A total of 571 filters and 1,227 days of CKRT were analyzed. Exposures: Liver disease, sepsis in the absence of liver disease, and sepsis with liver disease. Outcomes: Filter life and metabolic complications per 100 CKRT days. Analytical Approach: Linear mixed-effects model and generalized linear mixed-effects models. Results: The majority of patients were male (91; 71.1%), 32 (25%) had liver disease, and 29 (22.7%) had sepsis without liver disease. Median filter life was 50.0 (interquartile range, 22.0-118.0) hours, with a maximum of 322 hours, and was significantly lower (33.5 [interquartile range, 17.5-60.5] h) in patients with liver disease. Calcium-containing replacement solutions were used in 41.6% of all CKRT hours and reduced intravenous calcium requirements by 31.7%. Hypocalcemia (ionized calcium <0.85 mmol/L) and hypercalcemia (total calcium >10.6 mg/dL) were observed in 6.0 and 6.7 per 100 CKRT days, respectively. Citrate accumulation was observed in 13.3% of all patients and was associated with metabolic acidosis in 3.9%, which was not significantly different in patients with liver disease (9.3%; P = 0.2). Limitations: Lack of control groups that used calcium-free dialysate and replacement solutions with RCA-CKRT. Possible overestimation of filter life from incomplete data on cause of filter failure. Conclusions: Our study suggests that RCA-CKRT with calcium-containing solutions is feasible and safe in critically ill patients, including those with sepsis and liver disease.
引用
收藏
页码:550 / U70
页数:11
相关论文
共 50 条
  • [1] Simplified regional citrate anticoagulation using a calcium-containing replacement solution for continuous venovenous hemofiltration
    Zhang, Ling
    Liao, Yujie
    Xiang, Jin
    Qin, Wei
    Wu, Xiaodong
    Tang, Yi
    Yang, Yingying
    Chen, Zhiwen
    Fu, Ping
    JOURNAL OF ARTIFICIAL ORGANS, 2013, 16 (02) : 185 - 192
  • [2] Calcium-containing versus calcium-free replacement solution in regional citrate anticoagulation for continuous renal replacement therapy: a randomized controlled trial
    Wei, Tiantian
    Tang, Xin
    Zhang, Ling
    Lin, Li
    Li, Peiyun
    Wang, Fang
    Fu, Ping
    CHINESE MEDICAL JOURNAL, 2022, 135 (20) : 2478 - 2487
  • [3] Regional Citrate Anticoagulation for PrismaFlex Continuous Renal Replacement Therapy
    Burry, Lisa D.
    Tung, David D.
    Hallett, David
    Bailie, Toni
    Carvalhana, Virginia
    Lee, David
    Rarriganesh, Steve
    Richardson, Robert
    Mehta, Sangeeta
    Lapinsky, Stephen E.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1419 - 1425
  • [4] Semiautomated Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy: An Observational Study in Young Children
    Liet, Jean-Michel
    Baleine, Julien
    Demaret, Pierre
    Mounier, Sophie
    Porcheret, Florence
    Joram, Nicolas
    Chenouard, Alexis
    PEDIATRIC CRITICAL CARE MEDICINE, 2022, 23 (09) : E429 - E433
  • [5] Regional citrate anticoagulation for continuous renal replacement therapy
    Kindgen-Milles, Detlef
    Brandenburger, Timo
    Dimski, Thomas
    CURRENT OPINION IN CRITICAL CARE, 2018, 24 (06) : 450 - 454
  • [6] Ionized calcium measurements during continuous renal replacement therapy with regional citrate anticoagulation
    Zatorski, Pawel
    Abokhouskaya, Nadzeya
    Lacki, Piotr
    Kolacz, Marcin
    Trzebicki, Janusz
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (03) : E107 - E109
  • [7] Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care
    Doidge, James C.
    Gould, Doug W.
    Sadique, Zia
    Borthwick, Mark
    Hatch, Robert A.
    Caskey, Fergus J.
    Forni, Lui
    Lawrence, Robert F.
    MacEwan, Clare
    Ostermann, Marlies
    Mouncey, Paul R.
    Harrison, David A.
    Rowan, Kathryn M.
    Young, J. Duncan
    Watkinson, Peter J.
    JOURNAL OF CRITICAL CARE, 2023, 74
  • [8] Regional citrate anticoagulation for continuous renal replacement therapy in children
    Prada Rico, Mayerly
    Fernandez Sarmiento, Jaime
    Rojas Velasquez, Ana Maria
    Gonzalez Chaparro, Luz Stella
    Gastelbondo Amaya, Ricardo
    Mulett Hoyos, Hernando
    Tibaduiza, Daniel
    Quintero Gomez, Ana Maria
    PEDIATRIC NEPHROLOGY, 2017, 32 (04) : 703 - 711
  • [9] Citrate Anticoagulation for Continuous Kidney Replacement Therapy: An Embarrassment of RICH-es
    Szamosfalvi, Balazs
    Yessayan, Lenar T.
    Heung, Michael
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (01) : 146 - 150
  • [10] Regional citrate anticoagulation with continuous renal replacement therapy as a cause of hypercalcemia
    Needleman, Leor
    Hughes, Michael S.
    Fatehi, Pedram
    Sellmeyer, Deborah E.
    ARCHIVES OF OSTEOPOROSIS, 2024, 19 (01)